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PCoagulation
he Risk of Hemorrhage Among
atients With Warfarin-Associated Coagulopathy
avid A. Garcia, MD,* Susan Regan, PHD,† Mark Crowther, MD,‡ Elaine M. Hylek, MD, MPH§
lbuquerque, New Mexico; Boston, Massachusetts; and Hamilton, Ontario, Canada
OBJECTIVES Among warfarin-treated patients with international normalized ratio (INR)5, we sought to
determine the risk of major bleeding within 30 days.
BACKGROUND For warfarin-treated patients, the risk of bleeding increases as the INR rises, particularly if the
INR exceeds 4. The 30-day risk of hemorrhage among outpatients with excessively prolonged
INR values is unknown.
METHODS To assess anticoagulation care in the U.S., a cohort of 6,761 patients taking warfarin was
prospectively assembled from 101 participating sites (43% were community-based cardiology
practices). From this cohort, 1,104 patients were identified with a first episode of INR 5.
RESULTS A total of 979 met eligibility criteria; complete follow-up information was available for 976
(99.7%). Ninety-six percent (n  937) of patients had an INR value between 5 and 9; 80%
of INR values were 7. Thirteen patients (1.3%) experienced major hemorrhage during the
30-day follow-up period; among patients whose INR was 5 and 9, 0.96% experienced major
hemorrhage. None of the bleeding events was fatal. Intervention with vitamin K was uncommon
(8.7%). Warfarin doses were withheld for the majority of patients. Fifty percent of patients who
were managed conservatively and retested on day 4 or 5 had an INR of 2.0 or less.
CONCLUSIONS For warfarin-treated outpatients presenting with an INR 5 and 9, the 30-day risk of
major bleeding is low (0.96%). Intervention with vitamin K among asymptomatic patients
presenting with an INR 9 is not routine practice in the U.S. (J Am Coll Cardiol 2006;
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.09.05847:804–8) © 2006 by the American College of Cardiology Foundation
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earfarin is a commonly prescribed anticoagulant used to
reat or prevent arterial and venous thrombosis. Because
arfarin has a narrow therapeutic index, patients routinely
ndergo phlebotomy or capillary blood sampling to measure
prothrombin time, the laboratory assessment of anticoag-
lant effect. The prothrombin time is standardized between
aboratories as the international normalized ratio (INR). For
ost indications, an INR value between 2.0 and 3.0 is
argeted.
The narrow therapeutic index of warfarin is highlighted
y the marked increase in the risk of major hemorrhage
ssociated with INR values that exceed 4.0 (1–4). Although
he association between an INR 4 and increased risk of
emorrhage is well documented, published evidence docu-
enting the absolute 30-day bleeding risk for an individual,
symptomatic patient who presents with a supratherapeutic
NR is limited. This uncertainty fuels patient fear and
hysician anxiety. In one prospective study of 114 asymp-
omatic patients presenting with INR values 6.0, 5 expe-
ienced a major hemorrhage during 14 days of follow-up
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ccepted September 13, 2005.4.4%, 95% confidence interval [CI] 1.4% to 9.9%) com-
ared to none of 268 patients whose INR was in the target
ange (5). In a retrospective case series, 3 of 23 patients
12.5%) whose INR values exceeded 10.0 had clinically
mportant bleeding (follow-up interval was not specified)
6). In contrast, two other retrospective studies (in which
ength of follow-up was not specified) have suggested that
or asymptomatic patients whose INR value is6.0, the risk
f major hemorrhage is 1% (7,8). All of the aforemen-
ioned studies were limited by small size.
It is widely accepted that patients taking warfarin who
resent with evidence of active bleeding and INR prolon-
ation should be given coagulation factor replacement (most
ften in the form of plasma products) and vitamin K (9).
or asymptomatic patients with warfarin-associated coagu-
opathy, however, management strategies vary. Although
ow-dose oral vitamin K has been shown to return an
levated INR to the therapeutic range more rapidly than
lacebo (10,11), many providers choose simply to withhold
arfarin from such patients, allowing the INR to decline
pontaneously (12). This inconsistency of vitamin K use is
ikely explained by the uncertainty surrounding the short-
erm risk of bleeding faced by these patients.
To estimate the 30-day risk of hemorrhage among patients
ith an excessively prolonged INR, we collected data
rospectively from a large observational cohort. By better
efining the bleeding risk in this population, we hoped to
rovide guidance to physicians caring for patients with
xcessive prolongation of their INR. Our secondary aim was
o describe the management practices (e.g., frequency of
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y the anticoagulation providers who enrolled patients in
his study.
ETHODS
ite recruitment. A prospective cohort was assembled in
rder to assess anticoagulation care in the U.S. (13). Regis-
ered users of CoumaCare software (Bristol-Myers Squibb
formerly DuPont Pharmaceuticals], Princeton, New Jersey)
ere invited to participate by letter and through a study
ebsite. CoumaCare is a software program that was freely
vailable and used by many anticoagulation management
ervices for clinical purposes such as patient tracking, data
ntry, and record keeping. The program does not make
osing or follow-up interval recommendations. A total of
74 individual site registrations were received by McKesson
BOC BioServices (Rockville, Maryland), the designated
egistry specialists for the study. Of these, 101 sites had the
echnologic capability and the review board approval nec-
ssary to participate. All sites had at least one dedicated
rovider managing warfarin, usually within the setting of a
ommunity-based, physician group practice. Patients were
nvited to participate in the registry either by letter or in
erson (at the time of a routine appointment). To be eligible
or inclusion in the registry, patients had to be 18 years of
ge or older and provide written informed consent. The
articipation of sites and patients was voluntary. For all centers,
cKesson HBOC provided individual on-site training about
ow to recruit patients, obtain consent, and transmit data.
dverse event reporting was mandatory, and study person-
el were trained to carry out such reporting with rigor
ufficient to meet federal regulatory requirements. Enroll-
ent began in April 2000 and ended in February 2002.
ata management. Encrypted data from each site were
ransmitted to the independent data-coordinating center
eekly (McKesson HBOC BioServices). Missing data fields
nd data entry errors were flagged and resolved directly with
he sites before data were transferred to the study investi-
ators. A direct query from the data-coordinating center to
he reporting site was triggered by any interval in INR
esting that exceeded 45 days or any INR value 10 or
0.8. Resolution of the flag relating to the INR testing
nterval required validation of warfarin status and confirma-
ion that the gap was not related to an adverse event. Study
nvestigators were blinded to the identification and location
f participating practices and patients.
atients and outcomes. Patients whose INR measurement
as 5.0 were identified. For patients who had more than
Abbreviations and Acronyms
AF  atrial fibrillation
CI  confidence interval
INR  international normalized ratione such qualifying INR value, only the first occurrence was considered. To be eligible, the index INR value had to: 1) be
ccompanied by a progress note (to classify provider man-
gement); and 2) occur more than 60 days before the site’s
nal study data transmission (to enable complete follow-up
y McKesson HBOC).
For each eligible patient, an investigator (D.A.G. or
.M.H.) reviewed the anticoagulation progress notes and
ollow-up INR values recorded during the 60 days after the
ndex INR measurement. The primary outcome of interest
as major hemorrhage, defined as bleeding that was fatal,
ed to hospitalization with transfusion of at least 2 U of
acked red blood cells, or occurred at a critical site (e.g.,
ntracranial, retroperitoneal). All other bleeding was consid-
red minor. Occurrence of an arterial or venous thrombo-
mbolic event in the 30-day follow-up period was also
ecorded. All major events were validated by an investigator
D.A.G. or E.M.H.) and directly verified with the site
irector by McKesson HBOC. For each patient, the fol-
owing data were also recorded: number of days warfarin
as withheld, number of days until the first repeat INR was
erformed, number of days until an INR value 4.0 was
ocumented, and the presence or absence of documented
itamin K use.
tatistical analysis. The effect of vitamin K on the risk of
ajor hemorrhage was assessed with logistic regression
sing a general estimating equation model to account for
ariation within sites. The model included terms for index
NR, age, and vitamin K (14).
The study protocol was approved by Western Institu-
ional Review Board (WIRB), Olympia, Washington, the
nstitutional review board at Massachusetts General Hospi-
al, and local review boards where they existed.
ole of the funding source. The funding source had no
ole in the collection, analysis, or interpretation of the data
r in the decision to submit the study for publication.
ESULTS
n the anticoagulation management study, 6,761 patients
ere enrolled from 38 states providing 5,961 person-years
f observation. Of the 101 clinical sites that participated, 98
ere community-based physician office practices, and 3
ere academic practices. Forty-three percent of the
ommunity-based sites were cardiology group practices.
he most common indications for warfarin therapy in-
luded atrial fibrillation (AF) (52%), prosthetic heart valve
15%), and venous thromboembolism (14%). Overall, 83%
f patients were 60 years of age or greater; 22% were age 80
ears or greater. Among patients with AF, 46% had hyper-
ension, 26% coronary artery disease, 15% diabetes mellitus,
nd 8% history of stroke.
From the overall cohort, 1,104 patients with a first
bserved INR 5 were identified; 979 (89%) met the
ligibility criteria. Nearly all of the excluded patients were
eemed ineligible because they had an elevated INR re-
orded fewer than 60 days before the site’s final data
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INR Prolongation and Bleeding Risk February 21, 2006:804–8ransmission. Of the 979 included patients, 39% were
eceiving warfarin for AF and 29% had a prosthetic heart
alve. The mean age was 69 years (range 20 to 94), and 50%
ere women. Sixty-two patients (6%) had been taking
arfarin for 3 months, 96% (n  937) of the patients had
n index INR value between 5 and 9, 80% of index INR
alues were 7 (Table 1).
utcomes. ADVERSE EVENTS ANDDOCUMENTEDVITAMIN
USE. Of the 979 patients, follow-up was complete for 976
99.7%). Overall, 13 patients (1.3% [95% CI 0.6 to 2.1])
xperienced a major hemorrhage during the first 30 days
fter the index INR; the majority occurred within one week
Table 2). Most of these events were gastrointestinal in
rigin, and none was fatal. Among the 934 patients with an
NR 9, 9 (0.96%) sustained a major hemorrhage. Four
9.5%) of the 42 patients whose INR was 9.0 or greater
xperienced a major bleed. Thirty-four patients (3.5%)
eported minor bleeding; all such cases were self-limited
xcept two patients whose epistaxis required cautery in the
mergency department. One patient with a very elevated
NR (but no sign of bleeding) was admitted to the hospital
or observation and warfarin reversal. Thromboembolic
vents were infrequent. Three patients (0.3%) sustained an
schemic event during the 30-day follow-up period (two
trokes and one peripheral arterial embolism).
Most patients were managed by withholding subsequent
arfarin doses. For different subgroups, the mean number
f days without warfarin is shown in Table 3. Vitamin K
able 1. Characteristics of Patients With an INR 5.0
n  979)
ean age 69.5  13
(range  20–94)
ender
Female 494 (50.5)
ace
White 883 (90.2)
Black 28 (2.9)
Hispanic 16 (1.6)
Asian 7 (0.7)
American Indian 4 (0.4)
Unknown/other 41 (4.2)
ndication for warfarin
Atrial fibrillation 386 (39.4)
Prosthetic heart valve(s) 280 (28.6)
Venous thromboembolism 135 (13.8)
Cerebrovascular accident 78 (8.0)
CHF/cardiomyopathy/LV thrombus 26 (2.7)
Atherosclerosis, peripheral vascular
disease, CAD, myocardial infarction
25 (2.6)
Systemic arterial embolism 11 (1.1)
Other 38 (3.9)
ean index INR 6.5
umber of patients with index INR 5, 7 783 (80%)
umber of patients with index INR 7, 9 154 (15.7%)
umber of patients with index INR 9 42 (4.3%)
atients with documented vitamin K use 85 (8.7%)
AD  coronary artery disease; CHF  congestive heart failure; INR  interna-
ional normalized ratio; LV  left ventricular.se, as documented in the progress notes in the Coumacare
database, was not routine. The progress notes of 85 patients
8.7%) contained evidence that vitamin K was given. The
ose of vitamin K was not available for five patients. Compared
o patients with an index INR between 5 and 9, vitamin K
se was more common among patients whose index INR
as 9 (62% vs. 7%). When given, vitamin K was pre-
cribed orally more than 90% of the time; the most common
oses were 2.5 mg (60%), 5 mg (24%), and 1.25 mg (11%).
n the U.S., vitamin K for oral administration is available
nly in 5-mg tablets. Of the 85 patients who were treated
ith vitamin K, one patient who received a 10-mg dose
xperienced an arterial embolus requiring embolectomy.
The effect of vitamin K on the risk of major hemorrhage
as not statistically significant in the univariate analysis
odds ratio 0.85 [95% CI 0.11 to 6.67]; p  0.88) or in the
ogistic model adjusting for index INR and age (odds ratio
.76 [95% CI 0.10 to 6.00]; p  0.80). The small number
f major bleeding events in our study precludes definitive
ssessment of the relationship between vitamin K use and
he risk of hemorrhage.
ATIENT FOLLOW-UP AND SUBSEQUENT INR MEASURE-
ENT. Of the 979 patients with an INR of 5.0 or greater,
2 patients had no subsequent INR measurements, 6
atients were taken off warfarin, 3 died of causes unrelated
able 2. Age, Gender, Index INR Value, and Site
f Hemorrhage for Each of the 13 Individuals With
ajor Bleeding*
Age (yrs), Gender INR Site of Bleed
63, F 13.1 Gastrointestinal
89, M 7.0 Retroperitoneal
69, F 7.7 Gastrointestinal
53, F 8.0 Gastrointestinal
78, M 16.1 Gastrointestinal
74, M 7.0 Gastrointestinal
72, M 11.0 Gastrointestinal
80, F 9.2 Gastrointestinal
79, M 5.6 Gastrointestinal
81, M† 6.4 Soft tissue
86, M† 6.7 Gastrointestinal
60, F† 8.0 Gastrointestinal
66, F† 5.8 Unknown
The first 9 patients listed experienced major hemmorrhage 0–14 days after the index
nternational normalized ratio (INR) value was recorded. †Patients who experienced
leeding 15–30 days after the index INR was recorded.
able 3. Mean Number of Days Warfarin Was Withheld by
ndex INR and Target INR Range*
ndex
INR
Target INR Range
2.0–3.0 (n  558) 2.5–3.5 (n  304)
% of
Total
Mean Days
Held
% of
Total
Mean Days
Held
–7 86% (482) 1.9 88% (268) 1.5
–9 12% (67) 2.6 11% (33) 2.3
9 1.6% (9) 4.2 1% (3) 2.7
Excluded: 85 patients who were given vitamin K, 16 patients with missing vitamin
data, and an additional 16 patients for whom the number of days held could not beetermined.
INR  international normalized ratio.
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February 21, 2006:804–8 INR Prolongation and Bleeding Risko warfarin, 2 transferred their warfarin management to
nother provider, and 1 patient was lost to follow-up. The
ime elapsed before the first repeat INR varied: 39% of
atients were retested within three days, and 75% were
etested within the first week. Of the 239 patients whose
rst follow-up INR occurred 8 or more days after the index
NR, 120 (50%) were scheduled for follow-up7 days after
he index INR, 50 (21%) missed an earlier scheduled
ppointment, 50 (21%) had no documented reason for the
ollow-up interval chosen, 14 (6%) were hospitalized, and 5
2%) had other reasons provided. For the patients whose
arfarin was held (but for whom no vitamin K was
rescribed), Figure 1 shows the median INR result among
atients tested on each of the first seven days after the index
easurement. Only the first follow-up INR value for any
atient was used for this analysis. Of the patients retested on
ay 4 or 5, nearly 50% had an INR of 2.0 or less.
ISCUSSION
he principal finding of our study is that for warfarin-
reated asymptomatic outpatients with an INR value 5,
he risk of major hemorrhage within 30 days is low (1.3%).
t is noteworthy that these INR results were obtained in
outine practice, and that 96% of index INR values were
9.0. The likelihood that our results fairly estimate the
leeding risk among such patients is high because our study
ncluded nearly 1,000 individuals identified from a cohort of
,761 patients, 22% of whom were age 80 years or greater.
urthermore, our finding is consistent with two previously
eported, smaller, single-center studies of 248 patients and
igure 1. Box and whisker plot of the next consecutive international norm
f days between the index and next INR date. The boxes delineate the inte
he middle of the box represents the median. The whiskers reach to the
ox. Points more extreme than that are individually plotted. Patients for w
ot interrupted have been excluded from this analysis.1 patients, respectively (7,8). The participation of 101 (redominantly community-based anticoagulation sites in
he present study enhances the generalizability of our
ndings.
The difference between the proportion of patients suffer-
ng major hemorrhage in our cohort and the higher propor-
ion previously reported by Hylek et al. (5) may be explained
y several important differences in the two studies. First, the
revious study included only 114 patients, and the 95% CI
urrounding the point estimate of major hemorrhage risk
as wide. Second, the previous study included a population
ith characteristics that might be expected to increase the
verall rate of hemorrhage: 100% of index INR values were
6 (14% were 10), the mean index INR was 8.1, the
ean age was 71 years, and 13% of patients had been taking
arfarin for 3 months. By comparison, the present study
ncluded a population in which only 3% of index INR values
ere 10, the mean index INR was 6.5, the mean age was
9, and only 6% of patients had been taking warfarin for3
onths. International normalized ratio, age, and the early
hase of therapy have all been shown to be risk factors for
ajor hemorrhage among patients taking warfarin (15–19);
NR prolongation conveys the highest risk. During 14 days
f follow-up in a previous study by Hylek et al. (5), there
ere no major hemorrhagic events among 268 patients
hose INR was in the target range.
Administration of vitamin K, as documented in the
oumaCare database, was uncommon in our cohort despite
vidence that low-dose oral vitamin K returns the INR
o the normal range more quickly than placebo without
ausing “over-reversal” of warfarin’s anticoagulant effect
d ratio (INR) value obtained after the index INR, plotted by the number
tile range, extending from the 25th to the 75th percentile. The bar across
extreme value that is within 1.5 times the interquartile range beyond the
vitamin K use was documented and patients whose warfarin therapy wasalize
rquar
most10,11,20–22). Published recommendations propose that
l
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INR Prolongation and Bleeding Risk February 21, 2006:804–8ow-dose oral vitamin K should be considered for patients
ith an INR 5 who are at risk for hemorrhage (23,24).
owever, the absence of high-quality evidence (coupled
ith the concern that vitamin K use may increase the risk of
hromboembolism) likely explains the low frequency of
itamin K use among patients whose INR was 9.
We acknowledge that the patients at highest risk for
leeding may have avoided hemorrhagic events because they
eceived vitamin K. However, because 894 individuals (91%
f our cohort) were managed without vitamin K, the
otential impact of any such selection bias on our results
ould be limited, particularly among patients whose INR
as 9, for whom documented vitamin K use was partic-
larly uncommon. In our analyses, vitamin K was not found
o have a significant effect on the risk of major hemorrhage,
ut the small number of bleeding events precludes definitive
ssessment. Because participation in our study was voluntary
nd required written informed consent, the potential for
election bias does exist. However, our cohort is represen-
ative of community-based practice based on patient age and
prevalence of medical conditions that is very similar to that
eported from other large ambulatory patient populations.
o be eligible, patients had to be 18 years of age or older.
wenty-two percent of the 979 patients in our study cohort
ere age 80 years or greater. Patients with a prior history of
leeding would have been eligible, if they were still taking
arfarin. The risk of major hemorrhage on warfarin is
argely driven by anticoagulation intensity, and all patients
n our study had an INR of 5.0 or greater. Because the
oumaCare software program does not incorporate deci-
ion aids or management tools, it is unlikely that use of this
racking system would have affected an individual’s risk of
leeding after an INR of 5.
In conclusion, this large cohort study indicates that for
symptomatic outpatients presenting with an INR between
and 9, the risk of major hemorrhage over the next 30 days
s low (0.96%). The small number (n  42) of patients
hose INR was 9 precludes the extrapolation of our
ndings to this subgroup. Individuals presenting with INR
alues over 9 (and perhaps other subpopulations) may
ndeed have a higher 30-day risk of bleeding. Appropriate
ssessment of the potential benefit of selected (or routine)
itamin K administration will only be accomplished with
andomized, placebo-controlled trials.
eprint requests and correspondence: Dr. David A. Garcia,
211 Lomas Northeast, MSC10 5550, Albuquerque, New Mexico
7131. E-mail: davgarcia@salud.unm.edu.
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